![BWeL: Brief intervention on weight loss trial — Nuffield Department of Primary Care Health Sciences, University of Oxford BWeL: Brief intervention on weight loss trial — Nuffield Department of Primary Care Health Sciences, University of Oxford](https://www.phc.ox.ac.uk/images/news-1/anon/@@images/20548258-5803-496f-ade4-79406bbb1fda.png)
BWeL: Brief intervention on weight loss trial — Nuffield Department of Primary Care Health Sciences, University of Oxford
![Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity](https://mma.prnewswire.com/media/2308428/image_2.jpg?p=facebook)
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
![Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | Nature Medicine Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-02026-4/MediaObjects/41591_2022_2026_Fig1_HTML.png)
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | Nature Medicine
![Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | Nature Medicine Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02026-4/MediaObjects/41591_2022_2026_Fig2_HTML.png)